Health Canada has approved Singulair (montelukast sodium) for the relief of symptoms of allergic rhinitis in people ages 15 and older. Allergic rhinitis, also known as hay fever, affects 20 percent to 25 percent of people in Canada and up to 75 percent of people with asthma. If poorly managed, the condition can increase the likelihood of asthma attacks and asthma-related hospital visits.
Read moreEspecially with the rising costs of health care (even for those of us with insurance), we have frequent discussions regarding the cost of... Read more »
Late Friday afternoon, January 22, 2010, the Food and Drug Administration (FDA) announced that they approved AMPYRA™ (dalfampridine,... Read more »
This is a study to evaluate the treatment of patients entering emergency rooms with asthma attacks when they are given an intravenous form of MK0476... Read more »
This is a study to determine if patients entering an emergency room with asthma attacks might benefit from an IV dose of an approved drug with the... Read more »
(Ivanhoe Newswire) -- Daily treatment with an inhaled steroid is the best way to keep kids with asthma breathing easy. Government researchers arrived... Read more »
Source: Medifocus Guidebook on: Hay Fever
strategies focus on impeding the function of the IgE antibodies, interruption of the release of antigen-induced autocoids (histamine and eicosanoids)... Read more »
Source: HealthCentral Encyclopedia
of asthma can be divided into long-term control and quick-relief medications.Long-term control medications are taken daily to maintain control of... Read more »